Nephrocare Health IPO – Company Analysis
The Nephrocare Health IPO, a Mainboard IPO, is a book-building issue of ₹871.05 Cr by Nephrocare Health Services Ltd., which delivers end-to-end dialysis care through a network of clinics across India and certain overseas markets. The company also provides services like diagnostics, hemodialysis, home and mobile dialysis, and wellness initiatives through an internal pharmacy.
During Fiscal 2025, Nephrocare serviced 29,281 patients and completed 2,885,450 dialysis treatments, accounting for nearly 10% of the country's dialysis patients. As of 30 September 2025, it completed 1,591,377 treatments and serviced 31,046 patients in India.
Nephrocare has strategic partnerships with prominent hospital chains including Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic, operating in-house dialysis facilities.
Nephrocare Health IPO Details
- IPO Open Date: Dec 10, 2025
- IPO Close Date: Dec 12, 2025
- Allotment Date: Dec 15, 2025 (Tentative)
- Refund Initiation: Dec 16, 2025 (Tentative)
- Expected Listing Date: Dec 17, 2025
- Price Band: ₹438 – ₹460 per share (Nephrocare Health IPO Price)
- Issue Size: ₹871.05 Cr (Fresh Issue: ₹353.40 Cr, OFS: ₹517.64 Cr)
- Listing: BSE & NSE
Industry Outlook
The dialysis and kidney care sector in India is witnessing strong growth due to increasing prevalence of chronic kidney diseases (CKD) and rising demand for organized, high-quality care. Nephrocare, being the largest network, is well-positioned to leverage this trend.
Company Financials (₹ Cr)
| Period Ended | Assets | Total Income | PAT | EBITDA | Net Worth | Reserves & Surplus | Total Borrowing |
|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 996.46 | 769.92 | 67.10 | 166.64 | 594.21 | 578.68 | 225.80 |
| 31 Mar 2024 | 806.02 | 574.72 | 35.13 | 99.66 | 423.55 | 408.57 | 243.37 |
| 31 Mar 2023 | 666.23 | 443.26 | -11.79 | 48.60 | 384.73 | 383.50 | 196.21 |
Cash Flows (₹ Mn)
| Activity | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Activities | 1,353.47 | 722.80 | 112.69 |
| Investing Activities | (1,250.73) | (506.60) | (782.06) |
| Financing Activities | 543.71 | 267.39 | 599.66 |
Revenue Bifurcation
(Source RHP)
The Objective of the Issue
- Capital expenditure for new dialysis clinics in India: ~₹129.11 Cr
- Pre-payment or scheduled repayment of borrowings: ~₹136 Cr
Listed Peers of Nephrocare Health Ltd.
| Company Name | Face Value (₹) | EPS (₹) | P/E (x) |
|---|---|---|---|
| Jupiter Life Line Hospitals | 10 | 29.47 | 51.10 |
| Rainbow Children Hospital | 10 | 23.97 | 56.84 |
| Dr. Agarwal’s Healthcare | 1 | 2.80 | 179.42 |
| Dr. Lal Path Labs | 10 | 28.09 | 52.47 |
| Metropolis Healthcare | 2 | 28.29 | 69.48 |
| Vijaya Diagnostics | 10 | 13.95 | 73.14 |
IPO's Strengths
- India’s and Asia’s largest dialysis chain
- Asset-light approach driving cost and operational efficiency
- Use of cutting-edge technologies ensuring quality care
- Organic growth supplemented by acquisitions and integration
- Experienced management and patient-focused leadership
IPO Weaknesses
- Dialysis services involve operational, medical, and legal risks
- Dependence on regulatory approvals in India
- Equipment failures and technological risks abroad
Nephrocare Health IPO GMP
- Neptune Logitek IPO GMP is ₹34 on 15 December, updated at 09:50 AM.
The gmp of ipo indicates limited listing gain expectations for new investors.
Nephrocare Health Limited IPO Summary
- Face Value: ₹2 per share
- Issue Price: ₹438 – ₹460 (Nephrocare Health IPO Price)
- Lot Size: 32 shares
- Issue Size: 1,89,35,819 shares (₹871.05 Cr)
- Offer for Sale: 1,12,53,102 shares (₹517.64 Cr)
- Fresh Issue: 76,82,717 shares (₹353.40 Cr)
- Listing At: BSE & NSE
- Issue Type: Book Built Issue IPO
- Registrar: Kfin Technologies Ltd.
Nephrocare Health IPO Lot Size
- Retail Investors: 1 Lot = 32 shares (₹14,720) to 13 Lots = 416 shares (₹1,91,360)
- S-HNI Investors: Minimum 14 Lots = 448 shares (₹2,06,080)
Nephrocare Health IPO Reservation
- Institutional: 50%
- Retail: 35%
- Non-Institutional: 15%
Nephrocare Health IPO Allotment Status
Check allotment status on the official registrar’s website or BSE.
Promoters And Management of Nephrocare Health Ltd.
- Pre-Issue Promoter Shareholding: 78.90%
- Post-Issue Promoter Shareholding: 71.49%
- Promoters include Vikram Vuppala, Bessemer Venture Partners Trust, Edoras Investment Holdings, Healthcare Parent Ltd., Investcorp Private Equity Fund II, Investcorp Growth Opportunity Fund
Nephrocare Health IPO Lead Managers
- ICICI Securities Ltd.
- Ambit Pvt. Ltd.
- IIFL Capital Services Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
Dividend Policy
The company has not paid any dividend during the past three financial years.
Conclusion
The Nephrocare Health IPO provides investors access to India’s largest dialysis network, backed by robust growth, rising demand, and an asset-light development strategy. Steady revenue growth and improving profitability highlight the long-term potential in healthcare services.
Investors should also consider Nephrocare Health IPO GMP, Nephrocare Health IPO Price, and IPO Dates before applying, keeping in mind high valuations, operational risks, and regulatory requirements.
